Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A single-cell RNA sequencing atlas of circulating leukocytes from healthy and osteosarcoma affected dogs

ABSTRACT: We used single-cell RNA sequencing to characterize the heterogeneity of circulating leukocytes in dogs, then employed the dataset to investigate how primary osteosarcoma (OS) tumors impacted circulating leukocytes.

ORGANISM(S): Canis lupus familiaris

PROVIDER: GSE225599 | GEO | 2023/04/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A single-cell RNA sequencing atlas of circulating leukocytes from healthy and osteosarcoma affected dogs

Project description:A single-cell RNA sequencing atlas of circulating leukocytes from healthy and osteosarcoma affected dogs

| PRJNA936588 | ENA

Dataset #3 for genome-wide analysis of heritable dog osteosarcoma in 3 breeds

Project description:Osteosarcoma in dogs is a spontaneously occurring disease with a global tumor gene expression signature indistinguishable from human pediatric tumors and clinical progression is remarkably similar. Unlike human OS, canine OS is a highly heritable disease with some large and giant dog breeds at >10x increased risk. We did a genome wide association study of osteosarcoma using the Illumina CanineHD genotyping array in three breeds: greyhound (mortality from OS = 26%), rottweiler (17%) and Irish wolfhound (IWH, 21%) and identified 33 inherited risk loci explaining 55 to 85% of phenotype variance in each breed. Data created for a genome-wide association studio of heritable osteosarcoma risk factors in dogs, including 267 racing greyhounds (153 affected (A) + 114 unaffected (U)), 135 rottweilers (80 A + 55 U), 141 IWH (76 A + 65 U) and 19 AKC greyhounds using the Illumina CanineHD array (~170,000 SNPs genomewide)

2013-11-12 | E-GEOD-51734 | biostudies-arrayexpress

Dataset #1 for genome-wide analysis of heritable dog osteosarcoma in 3 breeds

2013-11-12 | E-GEOD-51973 | biostudies-arrayexpress

Dataset #2 for genome-wide analysis of heritable dog osteosarcoma in 3 breeds

2013-11-12 | E-GEOD-51976 | biostudies-arrayexpress

Dataset #3 for genome-wide analysis of heritable dog osteosarcoma in 3 breeds

2013-11-12 | GSE51734 | GEO

Dataset #2 for genome-wide analysis of heritable dog osteosarcoma in 3 breeds

2013-11-12 | GSE51976 | GEO

Dataset #1 for genome-wide analysis of heritable dog osteosarcoma in 3 breeds

2013-11-12 | GSE51973 | GEO

Single-cell RNA sequencing reveals the cellular and molecular heterogeneity of treatment-naïve primary osteosarcoma in dogs

Project description:We used single-cell RNA sequencing to characterize the heterogeneity of canine osteosarcoma (OS) tumors.

2024-03-28 | GSE252470 | GEO

Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning [mouse data]

Project description:We developed a method using canine osteosarcoma in mouse xenografts to distinguish tumor-derived from host-response exosomal mRNAs. The model allows for the identification of canine osteosarcoma-specific gene signatures by RNA sequencing and a species-differentiating bioinformatics pipeline. An osteosarcoma-associated signature consisting of five gene transcripts was validated in dogs with osteosarcoma. Serum/plasma exosomes were isolated from 53 dogs in distinct clinical groups (“healthy”, “osteosarcoma”, “other bone tumor”, or “non-neoplastic disease”). Pre-treatment samples from osteosarcoma cases were used as the training set and a validation set from post-treatment samples was used for testing, classifying as “osteosarcoma–detected” or “osteosarcoma–NOT detected”. Dogs in a validation set whose post-treatment samples were classified as “osteosarcoma–NOT detected” had longer remissions, up to 15 months after treatment. In conclusion, we identified a gene signature predictive of molecular remissions with potential applications in the early detection and minimal residual disease settings. These results provide proof-of-concept for our discovery platform and its utilization in future studies to inform cancer risk, diagnosis, prognosis, and therapeutic response.

2021-09-03 | GSE183190 | GEO

Development of an exosomal gene signature to detect residual disease in dogs with osteosarcoma using a novel xenograft platform and machine learning [canine data]

2021-09-03 | GSE183189 | GEO